Univariate analysis of demographic characteristics and clinical pathological characteristics of cancer subjects with and without sarcoid-like granuloma
| Variable | Cancer only | Cancer and granuloma | p-value | OR (95 CI) |
| Subjects n | 134 | 46 | – | – |
| Age at cancer diagnosis | 57.9±14.3 | 58.3±12.96 | 0.860 | – |
| Average years of follow-up | 6.0±6.4 | 5.5±5.1 | 0.615 | |
| Male | 53 (39.5) | 24 (52.1) | 0.137 | 1.67 (0.85–3.27) |
| European-American | 56 (41.8) | 16 (34.8) | 0.403 | 0.74 (0.37–1.49) |
| Hispanic | 57 (42.5) | 12 (26.1) | 0.050 | 0.48 (0.23–1) |
| African American | 17 (12.7) | 8 (17.4) | 0.428 | 1.45 (0.58–3.62) |
| Asian | 2 (1.4) | 8 (17.4) | 0.001 | 13.90 (2.83–68.2) |
| Smokers | 70 (52.2) | 17 (36.9) | 0.087 | 0.55 (0.27–1.09) |
| Average years of smoking | 30.92 | 36.4 | 0.243 | – |
| Alive <2 years | 20 (46.5) | 12 (80) | 0.033 | 4.6 (1.13–18.65) |
| Alive <4 years | 40 (50.6) | 20 (80) | 0.013 | 3.9 (1.33–11.42) |
| Alive <6 years | 48 (51.1) | 30 (85.7) | 0.001 | 5.75 (2.05–16.1) |
| Alive <10 years | 57 (51.3) | 35 (85.4) | <0.0001 | 5.53 (2.15–14.18) |
| Alive >10 years | 16 (69.6) | 5 (100) | – | – |
| Bladder cancer | 7 (5.2) | 3 (6.5) | 0.741 | 1.27 (0.31–5.11) |
| Breast cancer | 37 (27.7) | 8 (17.4) | 0.171 | 0.55 (0.24–1.3) |
| Colon cancer | 7 (5.2) | 5 (10.9) | 0.195 | 2.21 (0.67–7.35) |
| Lung cancer | 30 (22.4) | 6 (13) | 0.177 | 0.52 (0.2–1.34) |
| Lymphoma | 15 (11.2) | 6 (13) | 0.736 | 1.19 (0.43–3.28) |
| Melanoma | 18 (13.4) | 5 (10.9) | 0.654 | 0.79 (0.27–2.25) |
| Pancreatic cancer | 4 (3) | 3 (6.5) | 0.296 | 2.27 (0.49–10.54) |
| RCC | 8 (6) | 1 (2.2) | 0.329 | 0.35 (0.04–2.88) |
| Sarcoma | 2 (1.5) | 3 (6.5) | 0.100 | 4.61 (0.75–28.48) |
| Prostate cancer | 6 (4.4) | 6 (13) | 0.055 | 3.2 (0.97–10.47) |
| Cancer stage 4 | 72 (57.6) | 6 (13) | <0.0001 | 0.17 (0.07–0.44) |
| Surgery | 86 (67.2) | 26 (56.5) | 0.798 | 0.91 (0.43–1.92) |
| Radiotherapy | 69 (53.9) | 13 (28.3) | 0.020 | 0.41 (0.2–0.87) |
| Chemotherapy | 90 (70.3) | 20 (43.5) | 0.020 | 0.42 (0.20–0.87) |
| mAb therapy | 55 (43.0) | 8 (17.4) | 0.011 | 0.33 (0.14–0.78) |
Data are presented as mean±sd or n (%), unless otherwise stated. RCC: renal cell carcinoma; mAb: monoclonal antibody therapy.